15 May 2026

Osteopore secures market access to Malaysian orthopaedic bone reconstruction market

Highlights

- **Regulatory access granted in Malaysia for Osteopore's orthopaedic portfolio, including the Company's centerpiece high tibial osteotomy (HTO) solution and other bone grafting applications.**
- **As the implants are produced from biomaterials (not from cadaveric or animal sources), they offer an option that aligns with considerations important to Muslim patients.**
- **Osteopore will now establish commercial representation and begin customer engagement activities in Malaysia.**
- **In 2025, the Malaysian bone graft and substitute market valuation was approximately USD 250-300m (AUD 360-465m). It is expected to grow at a compound annual growth rate (CAGR) of 7-9% over the next 2 years[1].**

Australian-Singaporean regenerative medicine company **Osteopore Limited** (**ASX: OSX**; **Osteopore** or **Company**) – a global leader in 3D-printed biomimetic and bioresorbable implants – is delighted to announced that it has received regulatory access that allows its entry into Malaysia's orthopaedic bone reconstruction market. The approved portfolio includes the Company's flagship high tibia osteotomy (HTO) product and additional solutions for bone grafting applications.

[1] https://www.marketsizeandtrends.com/report/bone-graft-and-substitute-market/

Osteopore's orthopaedic products leverage a 3D-printed micro-architecture that mimics cancellous bone to enable natural regeneration, ultimately leaving patients without permanent implants because the scaffold resorbs over time. As the implants are produced from biomaterials (not from cadaveric or animal sources), they offer an option that aligns with considerations important to Muslim patients- an aspect highlighted at Arab Health 2016 [2].

The Company will now move to secure commercial representation and commence customer engagement, with initial focus on major trauma centres including Hospital Kuala Lumpur, Hospital Sungai Buloh, and University Malaya Medical Centre[3].

The approval for Osteopore's orthopaedic products strengthens the Company's commercial presence in Malaysia, supplementing its craniofacial reconstruction as well as its recently-inked dental commercial partnership with DKSH Malaysia[4].

According to a market research report published in January 2026, the Malaysian bone graft and substitute market is projected to grow at a compound annual growth rate (CAGR) of between 7-9% for the next 2 years. In 2025, the market valuation was approximately USD 250-300m (AUD 360-465m)[1].

Commenting on obtaining regulatory access in Malaysia , CEO Dr Yujing Lim, said:
"This approval allows us to expand our important orthopaedic product line into Malaysia. We observed encouraging adoption patterns in Singapore, and given substantial similarities in treatment methodologies between Singapore and Malaysia, our team is focused to leverage on our experience in Singapore to approach the Malaysian market.

[2] https://www.khaleejtimes.com/lifestyle/health/muslim-friendly-way-to-3d-printed-implants

[3] Koshy et al., Cureus, 2025. doi: 10.7759/cureus.84107

[4] ASX announcement, "OSX partners DKSH for dental products in Malaysia", 25 Nov 2025.

"Leveraging regulatory reliance frameworks between Singapore and Malaysia helped streamline access, and our focus now is to establish strong commercial partnerships and engage leading trauma centres to support surgeons and their patients", said Dr Lim.

ENDS

This announcement has been authorised for release to the ASX by the Board of Osteopore Limited.

For more information, please contact:

Dr Yujing Lim
Chief Executive Officer
Osteopore Limited
E: lim_yujing@osteopore.com

Mark Leong
Executive Chairman
Osteopore Limited
E: mark_leong@osteopore.com

About Osteopore Limited

Osteopore Ltd. is a global medical technology company founded in Singapore and listed in Australia that commercialises products designed to enable natural bone healing across multiple therapeutic areas. Osteopore's patented technology fabricates specific micro-structured scaffolds for bone regeneration through 3D printing and bioresorbable material.

Osteopore's patent-protected scaffolds are manufactured using a proprietary manufacturing technique with a polymer that naturally dissolves over time to only allow natural and healthy bone tissue, significantly reducing the post-surgery complications commonly associated with permanent bone implants. Our 3D printing technology is unique to Osteopore.

Forward-Looking Statements

Some of the statements appearing in this announcement may be similar to forward-looking statements. You should be aware that such statements are only predictions and are subject to inherent risks and uncertainties. Those risks and uncertainties include factors and risks specific to the industries in which the Company operates and proposes to operate as well as general economic conditions, prevailing exchange rates and interest rates and conditions in the financial markets, among other things.

Actual events or results may differ materially from the events or results expressed or implied in any forward-looking statement. No forward-looking statement is a guarantee or representation as to future performance or any other future matters, which will be influenced by several factors and subject to various uncertainties and contingencies, many of which will be outside the Company's control. The Company does not undertake any obligation to update publicly or release any revisions to these forward-looking statements to reflect events or circumstances after today's date or to reflect the occurrence of unanticipated events.

No representation or warranty, express or implied, is made as to the fairness, accuracy, completeness or correctness of the information, opinions or conclusions contained in this announcement. To the maximum extent permitted by law, neither of the Company's Directors, employees, advisors or agents, nor any other person, accepts any liability for any loss arising from the use of the information contained in this announcement.

You are cautioned not to place undue reliance on any forward-looking statement. The forward-looking statements in this announcement reflect views held only as at the date of this announcement. This announcement is not an offer, invitation or recommendation to subscribe for or purchase securities by the Company. Nor does this announcement constitute investment or financial product advice (nor tax, accounting or legal advice) and is not intended to be used for the basis of making an investment decision. Investors should obtain their own advice before making any investment decision.